Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vector Tobacco was a biotechnology subsidiary of Vector Group that specialized in the development of reduced-nicotine tobacco products through genetic engineering. The company gained prominence for its Quest brand of cigarettes, which utilized genetically modified tobacco plants to offer varying levels of nicotine, including a nicotine-free option. Launched in 2003, these products were positioned as a tool for smokers seeking to reduce their chemical dependency on nicotine. Although the Quest line was eventually discontinued, Vector Tobacco's research represented a pioneering application of agricultural biotechnology to address public health concerns related to smoking. The company's parent, Vector Group, was acquired by Japan Tobacco in 2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vector Tobacco.